{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T04:05:52Z","timestamp":1749873952113,"version":"3.41.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>IMPORTANCE:<\/jats:title>\n            <jats:p>A characteristic pattern of bacterial and fungal septic shock is decreased left ventricular (LV) ejection fraction (LVEF) and modest dilatation of the LV. In survivors, the myocardial depression and dilatation are reversible within several days. In a cohort of 368 hospitalized COVID patients with shock from March 2020 to December 2021, 15 patients were identified with an echocardiogram determined depressed LVEF during acute shock, and a follow-up echocardiogram was performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>Myocardial dysfunction and dilatation associated with COVID-19 are reversible.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN, SETTING, AND PARTICIPANTS:<\/jats:title>\n            <jats:p>LVEF was determined by Simpson\u2019s rule and stroke volume (SV) was analyzed by Doppler. Based on the LVEF and cardiac index (CI), patients were categorized into groups with low or normal values using an ejection fraction of 45% and CI 2.2\u2009L\/min\/m<jats:sup>2<\/jats:sup> as the respective thresholds. A subset of 15 patients underwent serial echocardiography, which was performed at a median of 13 days (95% CI, 9\u201339 d) after the initial value.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MAIN OUTCOMES AND MEASURES:<\/jats:title>\n            <jats:p>The LVEF and LV volumes recorded during initial and follow-up echo were analyzed using paired <jats:italic toggle=\"yes\">t<\/jats:italic> test.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Comparing initial during acute shock with follow-up values, the mean (\u00b1 <jats:sc>sd<\/jats:sc>) LVEF was 35.3 \u00b1 8.1 vs. 43.8 \u00b1 3.47 (<jats:italic toggle=\"yes\">p<\/jats:italic> = 0.031), indexed SV 29.6 \u00b1 1.9\u2009mL vs. 31.7 \u00b1 2.3\u2009mL (<jats:italic toggle=\"yes\">p<\/jats:italic> = 0.522), LV end-diastolic volume 182 \u00b1 14.1\u2009mL vs. 152.1 \u00b1 12.9\u2009mL (<jats:italic toggle=\"yes\">p<\/jats:italic> = 0.025), and LV end-systolic volume 120.2 \u00b1 13.1\u2009mL vs. 90.1 \u00b1 12.1\u2009mL (<jats:italic toggle=\"yes\">p<\/jats:italic> = 0.025), respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS AND RELEVANCE:<\/jats:title>\n            <jats:p>Serial echocardiographic studies of COVID-19 shock patients with reduced LVEF and ventricular dilatation demonstrate reversibility of myocardial depression and dilation with no change in SV, a finding strikingly similar to that seen in bacterial and fungal-induced septic shock. Thus, COVID-19 (viral) induced septic shock may have a similar pathogenetic mechanism of myocardial dysfunction to that seen with bacterial or fungal sepsis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cce.0000000000001264","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T13:00:27Z","timestamp":1749819627000},"page":"e1264","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Reversible Myocardial Depression and Dilatation in COVID-19 Shock Patients"],"prefix":"10.1097","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7060-8738","authenticated-orcid":false,"given":"Matthew J.","family":"Fata","sequence":"first","affiliation":[{"name":"Hackensack University Medical Center, Hackensack, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven M.","family":"Hollenberg","sequence":"additional","affiliation":[{"name":"Emory University Hospital, Atlanta, GA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent","family":"Klinkhammer","sequence":"additional","affiliation":[{"name":"Westchester Medical Center, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Landers","sequence":"additional","affiliation":[{"name":"Hackensack University Medical Center, Hackensack, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Rockett","sequence":"additional","affiliation":[{"name":"Hackensack University Medical Center, Hackensack, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Tancredi","sequence":"additional","affiliation":[{"name":"Hackensack University Medical Center, Hackensack, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoltan","family":"Turi","sequence":"additional","affiliation":[{"name":"Hackensack University Medical Center, Hackensack, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph E.","family":"Parrillo","sequence":"additional","affiliation":[{"name":"Hackensack University Medical Center, Hackensack, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"key":"R1-20250613","doi-asserted-by":"crossref","first-page":"227","DOI":"10.7326\/0003-4819-113-3-227","article-title":"Septic shock in humans: Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy.","volume":"113","author":"Parrillo","year":"1990","journal-title":"Ann Intern Med"},{"key":"R2-20250613","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.amjcard.2021.05.029","article-title":"Hemodynamic profiles of shock in patients with COVID-19.","volume":"153","author":"Hollenberg","year":"2021","journal-title":"Am J Cardiol"},{"key":"R3-20250613","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"R4-20250613","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41569-020-00492-2","article-title":"Septic cardiomyopathy.","volume":"18","author":"Hollenberg","year":"2021","journal-title":"Nature Rev Cardiol"},{"key":"R5-20250613","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM199305203282008","article-title":"Pathogenetic mechanisms of septic shock.","volume":"328","author":"Parrillo","year":"1993","journal-title":"N Engl J Med"},{"key":"R6-20250613","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1084\/jem.183.3.949","article-title":"Tumor necrosis factor-alpha and interleukin-1 beta are responsible for in-vitro myocardial cell depression induced by human septic shock serum.","volume":"183","author":"Kumar","year":"1996","journal-title":"J Exp Med"},{"key":"R7-20250613","first-page":"R265","article-title":"The role of nitric oxide and cyclic GMP in human septic serum induced depression of cardiac myocyte contractility.","volume":"276","author":"Kumar","year":"1999","journal-title":"Am J Physiol"},{"key":"R8-20250613","doi-asserted-by":"crossref","first-page":"42619","DOI":"10.1074\/jbc.M508416200","article-title":"Human serum from patients with septic shock activates transcription factors STAT1, IRF1, NF-\u03baB and induces apoptosis in human cardiac myocytes.","volume":"280","author":"Kumar","year":"2005","journal-title":"J Biol Chem"},{"key":"R9-20250613","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1096\/fj.04-2519fje","article-title":"Protection against endotoxemia-induced contractile dysfunction in mice with cardiac-specific expression of slow skeletal troponin I.","volume":"19","author":"Layland","year":"2005","journal-title":"FASEB J"},{"key":"R10-20250613","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cvr\/cvaa106","article-title":"COVID-19 and the cardiovascular system: Implications for risk assessment, diagnosis, and treatment options.","volume":"116","author":"Guzik","year":"2020","journal-title":"Cardiovasc Res"}],"container-title":["Critical Care Explorations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000001264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T13:00:30Z","timestamp":1749819630000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000001264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":10,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cce.0000000000001264","relation":{},"ISSN":["2639-8028"],"issn-type":[{"value":"2639-8028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}